Wednesday, January 23, 2008

VIDEOMultiple Sclerosis

CBC.ca News - Health

VIDEOMultiple Sclerosis
New research gives hope to some (Runs 12:37)


http://www.cbc.ca/health/

New therapeutic target for treatment of multiple sclerosis
EurekAlert! Tue, 22 Jan 2008 7:40 AM PST
Montreal, January 22, 2007 – An international research team, led by a scientist from the Centre hospitalier de l’Université de Montréal (CHUM), has identified new therapeutic targets for the treatment of multiple sclerosis (MS). In the February issue of Nature Immunology, the team provides fresh answers concerning the role of novel adhesion molecules in the pathogenesis of MS, a chronic ...

Biotech Stock Gains on Bullish Forecast
Barron's - USA
In "Better the Second Time Around," Barron's Neil Martin wrote that Fampridine, which is used to improve the walking ability of patients with multiple ...
See all stories on this topic

Boost neurosurgery capacity, Ontario urged
Globe and Mail - Canada
"There's no effort whatsoever to develop a plan of action," Ms. Witmer said of the Liberal government. "It's really quite appalling to see the increase in ...
See all stories on this topic

Dieting with Montel Williams
amNewYork - New York,USA
... a man diagnosed with multiple sclerosis who tries to better himself each day. An added bonus? Reading the book made me flip on Montel's show -- a guilty ...
See all stories on this topic

Biogen Idec could make a large-scale acquisition following failed sale
Financial Times - London,England,UK
... four trials that need to be completed but are already showing indications for primary progressive MS, which composes up to 10% to 15% of the MS market. ...
See all stories on this topic

Better the Second Time Around
Barron's - USA
The Superman star invited Cohen to his Westchester home to discuss Acorda's research and potential products, including Fampridine-SR, a drug that held ...
See all stories on this topic

Acorda stock may rise if trials go well-Barron's
Reuters - USA
Its drug, Fampridine-SR, which held promise for the treatment of multiple sclerosis and spinal injuries, is going through Phase 3 clinical trials, ...
See all stories on this topic

First cloned embryo of adult human created
Independent - London,England,UK
... the technology of deriving cloned embryonic stem cells from patients with serious disorders such as Parkinson's disease, multiple sclerosis or diabetes. ...
See all stories on this topic

Outlook 2008: BioTech Offers Investment Longevity
Money Morning - USA
For instance, Campath, a drug originally intended to treat cancer, is also used to treat multiple sclerosis. Genzyme reported a 20% growth in revenue for ...
See all stories on this topic

Novartis achieves record results in
Ad-Hoc-News (Pressemitteilung) - Germany
... Phase IIIprogram to be conducted in relapsing-remitting multiple sclerosis(MS) to further evaluate its efficacy and safety. The programincludes FREEDOMS ...
See all stories on this topic

Novartis Achieves Record Results In 2007 Underscoring Benefits Of ...
ABN Newswire (press release) - Sydney,NSW,Australia
... in the largest worldwide Phase III program to be conducted in relapsing-remitting multiple sclerosis (MS) to further evaluate its efficacy and safety. ...
See all stories on this topic

0 Comments:

Post a Comment

Links to this post:

Create a Link

<< Home